UNSPSC 51351909: Promegestone

This classification denotes a steroid compound with the molecular formula C22H30O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9XE0V2SQYX, chemically known as 17alpha-methyl-1,7-propionylestra-4,9-dien-3-one but generally known as promegestone, which bears US NIH Compound Identifier 36709. European Medicines Agency schedules Promegestone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10086MIG.

UNSPSC 51351909 Promegestone, a Commodity code, covers pharmaceutical active ingredients and finished pharmaceutical products that state and local governments procure for healthcare delivery across their facilities. The recent activity under this code centers on generic multi-source pharmaceuticals and over-the-counter products distributed through authorized wholesalers to participating state and local government entities. State procurement alliances and health system purchasing collaboratives drive demand; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, structures acquisitions to span multiple jurisdictions, leveraging cooperative purchasing mechanisms to standardize supply chains and pricing across member states including Oregon. Vendors supply products with specific National Drug Codes, stock-keeping units, and universal product codes, and must certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act. Pricing structures vary—flat price, net price formats (NF30, NF60, NF90), or WAC-minus pricing—and successful vendors maintain contractual relationships with authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC) equipped with chargeback systems.

The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP (Solicitation Number S1070000015802) on January 20, 2026, with responses due March 26, 2026, to establish multi-year contracts for generic pharmaceuticals and OTC products effective July 1, 2026. Evaluation weights emphasize price competitiveness (75 percent), with administrative criteria including fixed pricing compliance, EDI capability, and the 3 percent administrative fee each representing 5 percent. Vendors must carry comprehensive insurance including $5 million commercial general liability, $2 million network security and privacy liability, and $2 million professional liability, and products must arrive with at least one year expiration dates and minimum six-month shelf life. MMCAP reserves discretion to award sole, dual, or multi-awards based on therapeutic considerations and member-specific needs, with contract terms of two years for new responders and extensions through June 30, 2028 for incumbents. No specific set-aside designations are noted in the solicitation documentation.